ANDA 210354, held by Ascent Pharmaceuticals. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 210354 (Methylphenidate Hydrochloride), held by Ascent Pharmaceuticals, was first approved by FDA on Dec 29, 2017, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 29, 2017 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride2.5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Rx |
| Oct 13, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 12, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 29, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters